PainReform (NASDAQ:PRFX) versus Journey Medical (NASDAQ:DERM) Financial Contrast

PainReform (NASDAQ:PRFX) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Earnings and Valuation

This table compares PainReform and Journey Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20,000.00	27.40	-$5.02 million	($736.66)	0.00
Journey Medical	$61.86 million	2.76	-$11.43 million	($0.37)	-16.76

PainReform has higher earnings, but lower revenue than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares PainReform and Journey Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Journey Medical	-14.82%	-35.57%	-10.88%

Analyst Ratings

This is a breakdown of current recommendations and price targets for PainReform and Journey Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1	0	0	0	1.00
Journey Medical	1	1	2	0	2.25

Journey Medical has a consensus target price of $13.00, suggesting a potential upside of 109.68%. Given Journey Medical’s stronger consensus rating and higher probable upside, analysts clearly believe Journey Medical is more favorable than PainReform.

Volatility and Risk

PainReform has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.

Insider and Institutional Ownership

37.3% of PainReform shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 15.0% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

PainReform beats Journey Medical on 8 of the 14 factors compared between the two stocks.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.